Lower face and neck neuromodulator injections are used to modulate muscle activity that may contribute to downturned corners of the mouth, chin dimpling, perioral lines, platysmal banding, and downward pull along the jawline. These treatments are intended to achieve subtle aesthetic improvement rather than complete muscle paralysis.

I understand that muscles of the lower face and neck are involved in essential functions, including speaking, chewing, swallowing, drinking, and maintaining lip competence. Treatment in these areas requires lower doses and greater precision than upper facial injections. Some lower face and neck neuromodulator uses may be considered off-label, which is common in aesthetic medicine and has been discussed with me.

In addition to the risks outlined in the primary neuromodulator consent, treatment of the lower face and neck may carry increased risk of temporary functional changes, including but not limited to difficulty drinking through a straw, changes in speech articulation, lip weakness or asymmetry, drooling, difficulty chewing, difficulty swallowing (dysphagia), and voice changes. I understand that these effects are typically temporary but may last weeks to months.

Difficulty breathing, swallowing, speaking, or voice changes may represent a medical emergency. If I experience any of these symptoms, I understand that I must call 911 or go to the nearest emergency room immediately and not wait to contact my injector.

I acknowledge that conservative dosing is intentionally used to minimize risk, touch-ups may be offered rather than higher initial doses, results may be subtle and individualized, and complete correction is not always achievable without increased risk.

By signing below, I acknowledge that I have read and understand this addendum, my questions have been answered to my satisfaction, I understand the unique risks of lower face and neck neuromodulator treatment, and I consent to proceed with treatment as discussed.

This consent addendum is intended to supplement, not replace, the primary Neuromodulator Treatment Consent.